Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T12:01:04.783Z.
Calculation as of: 2026-10-06T12:01:04.783Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 47b7d046e53ba400f53df530976eb059ace8f079140d97e9bcfa36b682aba175
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Assembly Biosciences, Inc.
Market Cap
$450.64M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$453.70M
EV/EBITDA Ratio
N/A
TTM Avg
81.39x
3Y Avg
32.05x
5Y Avg
24.98x
Market Cap
$447.43M
EV/EBITDA Ratio
0.44x
TTM Avg
1.11x
3Y Avg
1.11x
5Y Avg
1.11x
Market Cap
$471.57M
EV/EBITDA Ratio
8036.17x
TTM Avg
8683.24x
3Y Avg
8683.24x
5Y Avg
8683.24x
Market Cap
$478.54M
EV/EBITDA Ratio
N/A
TTM Avg
5.88x
3Y Avg
17.52x
5Y Avg
17.52x
Market Cap
$416.68M
EV/EBITDA Ratio
N/A
TTM Avg
10.71x
3Y Avg
10.71x
5Y Avg
10.71x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Assembly Biosciences, Inc. (ASMB) | $450.64M | N/A | N/A | N/A | N/A |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $453.70M | N/A | 81.39x | 32.05x | 24.98x |
| Capricor Therapeutics, Inc. (CAPR)vs › | $447.43M | 0.44x | 1.11x | 1.11x | 1.11x |
| NRC Health (NRC)vs › | $468.31M | 23.75x | 16.39x | 15.03x | 16.69x |
| Cerus Corporation (CERS)vs › | $471.57M | 8036.17x | 8683.24x | 8683.24x | 8683.24x |
| Editas Medicine, Inc. (EDIT)vs › | $428.16M | N/A | N/A | N/A | N/A |
| Contineum Therapeutics, Inc. (CTNM)vs › | $478.54M | N/A | 5.88x | 17.52x | 17.52x |
| Arvinas, Inc. (ARVN)vs › | $481.33M | N/A | N/A | N/A | N/A |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $416.68M | N/A | 10.71x | 10.71x | 10.71x |
| Carlsmed, Inc. (CARL)vs › | $415.93M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
